Novo Nordisk: successful weight-loss study

(CercleFinance.com) - Novo Nordisk reports that its phase 3b STEP UP study has met its primary endpoint, demonstrating statistically significant superior weight loss at week 72 with subcutaneous semaglutide 7.
2 mg versus placebo.

Based on a mean baseline body weight of 113 kg, those treated with semaglutide 7.2 mg achieved a 20.7% greater weight loss, compared with reductions of 17.5% with semaglutide 2.4 mg and 2.4% with placebo.

In addition, 33.2% of those receiving semaglutide 7.2 mg experienced weight loss of 25% or more, compared with 16.7% with semaglutide 2.4 mg and 0.0% with placebo. In the trial, semaglutide 7.2 mg appeared to have a safe and well-tolerated profile.


Copyright (c) 2025 CercleFinance.com. All rights reserved.